Navigation Links
GeoVax Labs, Inc. Third Quarter Financial Results and Operational Update
Date:11/15/2007

ng Board recommended that the trial be

stopped because it was not reaching its efficacy endpoints. GeoVax

responded to the discontinuance of Merck's trial by pointing out

significant differences between the GeoVax vaccine technology and the

technology used in the Merck trial.

GeoVax AIDS vaccines advancing in human trials represent a

significantly different vaccine approach, vaccine composition and

results to date than the Merck vaccine.

* Prototypes for the GeoVax vaccines were selected from a series of

trials in non-human primates for their ability to protect against

the development of AIDS when vaccinated individuals were

administered an AIDS causing virus. At each major step along the

development pathway, GeoVax vaccines providing the best protection

against AIDS were moved forward.

* GeoVax AIDS vaccines demonstrated excellent protective results in

non-human primate models, much better protective results than

reported for Merck's vaccine in similar models. GeoVax AIDS

vaccines protected 22/23 non-human primates for over 3 1/2 years

and 5/6 non-vaccinated controls died of AIDS post-AIDS virus

infection.

* GeoVax AIDS vaccines are designed to elicit protective antibodies

(Ab) as well as protective T cells (white blood cells) against the

AIDS virus. The Merck vaccine stimulates only T cells for providing

protection and does not include the Env protein of HIV which is the

target for protective antibody (Ab).

* Protective Ab has been difficult to elicit with HIV/AIDS vaccines.

GeoVax has approached this challenge by vaccinating with the

natural form of Env (HIV envelope antigens) under conditions that

elicit tightly binding Ab. GeoVax studie
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. GeoVax Successful HIV/AIDS Vaccine Trial Data Presented at AIDS Vaccine 2007 Conference
2. GeoVax Labs, Inc. Comments on Discontinuance of Mercks HIV Vaccine Trial
3. Excellent Results Received from GeoVaxs Full-Dose HIV/AIDS Vaccine Trial
4. Biopure Announces 2007 Third Quarter Financial Results
5. Gen-Probe Announces Webcast of Third Quarter 2007 Earnings Conference Call
6. The Quigley Corporation Reports Third Quarter Results, Increases Investment in Pharmaceutical R&D for Diabetic Neuropathy
7. Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results
8. QIAGEN N.V. (Nasdaq: QGEN) Invites You to Join Its Third Quarter 2007 Earnings Conference Call on the Web
9. Pharmacopeia Announces Third Quarter 2007 Financial Results
10. Emisphere Technologies, Inc. Announces 2007 Third Quarter Financial Results
11. PharmAthene to Webcast its Third Quarter Conference Call on November 13, 2007 at 4:30 P.M. Eastern Time
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)... 2015  AbbVie (NYSE: ABBV ) will ... Thursday, March 12, 2015. Richard A. Gonzalez , ... question and answer session at 8:30 a.m. Central time. ... will be accessible through AbbVie,s Investor Relations Web site ... session will be available later that day. ...
(Date:3/6/2015)... March 6, 2015 Troyen A. Brennan, M.D., ... CVS Health (NYSE: CVS ), will speak ... Washington, D.C. today.  Brennan will outline ... addressing health care cost and quality as the overall ... the first national pharmacy chain to stop selling tobacco ...
(Date:3/6/2015)... , March 6, 2015   Veracyte, Inc. ... demonstrating that diagnostic tests that use increasing numbers of ... reduce the specificity of test results, leading to an ... erroneously diagnosed as cancerous. In addition, these new data ... the malignancies leading to "false negatives." The data were ...
Breaking Medicine Technology:CVS Health Chief Medical Officer to Address National Business Group on Health on Value of Pharmacy Care in Evolving Health Care System 2CVS Health Chief Medical Officer to Address National Business Group on Health on Value of Pharmacy Care in Evolving Health Care System 3Veracyte Announces New Data that Inform Optimal Use of Molecular Testing in Preoperative Thyroid Nodule Assessment 2Veracyte Announces New Data that Inform Optimal Use of Molecular Testing in Preoperative Thyroid Nodule Assessment 3Veracyte Announces New Data that Inform Optimal Use of Molecular Testing in Preoperative Thyroid Nodule Assessment 4Veracyte Announces New Data that Inform Optimal Use of Molecular Testing in Preoperative Thyroid Nodule Assessment 5Veracyte Announces New Data that Inform Optimal Use of Molecular Testing in Preoperative Thyroid Nodule Assessment 6
(Date:3/6/2015)... As the Muscular Dystrophy Association continues to enhance ... hired two new Scientific Program Officers, Amanda Haidet-Phillips, Ph.D ... Grace Pavlath, Ph.D, who joined MDA late last year ... together will lead MDA as it accelerates new front-line ... types of neuromuscular and motor neuron diseases. ...
(Date:3/6/2015)... (PRWEB) March 06, 2015 Parents need ... fatal reality of substance use disorders. School programs like ... be marginally successful. NOPE, or Narcotics Overdose Prevention and ... according to Healthline News on Feb. 27th. ... and prescription opiate drugs, drug prevention proponents are lobbying ...
(Date:3/6/2015)... Anaheim, Cailfornia (PRWEB) March 06, 2015 ... lifestyle technology company, announced today the launch of ... save money on healthy and sustainable products at ... retailers. Makeena is exhibiting at Expo West Booth ... to search by gluten-free, Kosher, non-GMO, organic, Paleo, ...
(Date:3/6/2015)... TN (PRWEB) March 06, 2015 Since ... January 1, 2015, there has been an overwhelming demand ... an efficient and compliant CCM program. The Centers ... on several matters. , PYA’s updated white paper—“ ... this new guidance into a detailed, yet practical “how ...
(Date:3/6/2015)... 2015 Jvion, the Atlanta-based leader ... a Clostridium Difficile (C Diff) predictive use case ... use case is the latest in a broad ... infections, chronic conditions, and individual illnesses. Using the ... solution flags at risk individuals to help support ...
Breaking Medicine News(10 mins):Health News:MDA Adds Muscle Disease and ALS Leaders to Research Team 2Health News:MDA Adds Muscle Disease and ALS Leaders to Research Team 3Health News:MDA Adds Muscle Disease and ALS Leaders to Research Team 4Health News:A Harbor Village Detox Clinical Psychologist Encourages School Programs like NOPE to Positively Impact Awareness of Substance Use Disorders 2Health News:Makeena Launches App that Makes Healthy and Sustainable Products More Affordable for Shoppers 2Health News:Makeena Launches App that Makes Healthy and Sustainable Products More Affordable for Shoppers 3Health News:Updated PYA White Paper Meets Demand for Guidance on Providing and Billing Medicare for Chronic Care Management 2Health News:Jvion Predicts Patients at Risk of C Difficile Infection to Reduce Risk and Save Lives 2
... new study challenges the widespread perception that bulimia primarily ... Blair Waldorf, who battled bulimia on the show earlier ... American are 50 percent more likely than girls who ... girls from families in the lowest income bracket studied ...
... Start of a Long-Term Trend in Infant HealthWHITE PLAINS, N.Y., ... in 2007 - a finding that the March of Dimes ... trend in improved maternal and infant health. The preterm birth ... preterm) and among babies born to African American and white ...
... Solutions and Patient Questionnaires for Clinical Trials announced that it has ... to collect data from patients at home on electronic diaries in ... ... AZ (PRWEB) March 18, 2009 -- assisTek, the Leader in ...
... 18 Nuvilex, Inc. (OTC Bulletin Board: NVLX), formerly ... , the world,s first permanent tattoo ink designed to be ... alt.news 26.46 television segment shown on February 22, 2009 on ... and development of the ink as well as its use ...
... Suggests Parents Most Influence Teens, Decisions About SexWASHINGTON, March 18 ... 1% in 2007, according to data released today by the ... second year in a row that the teen birth rate ... decline in the teen birth rate. That is, after ...
... that the PSA test is a far from perfect tool ... offer conflicting views on the value of screening men with ... , But at least one leading oncologist says this much ... family history of prostate cancer should pay attention to a ...
Cached Medicine News:Health News:Black girls are 50 percent more likely to be bulimic than white girls 2Health News:Black girls are 50 percent more likely to be bulimic than white girls 3Health News:Preterm Birth Rate Drops 2Health News:Preterm Birth Rate Drops 3Health News:Preterm Birth Rate Drops 4Health News:Smart Phones to be used by assisTek to Collect Patient-Reported Outcomes in a Large Multinational Clinical Trial 2Health News:Smart Phones to be used by assisTek to Collect Patient-Reported Outcomes in a Large Multinational Clinical Trial 3Health News:Nuvilex' Infinitink Tattoo Ink Featured on PBS alt.news 26:46 TV Program 2Health News:Teen Birth Rate Up For Second Year in a Row 2Health News:2 Studies Conflict Over Value of Prostate Cancer Screening 2Health News:2 Studies Conflict Over Value of Prostate Cancer Screening 3
For the quantitative determination of direct & total bilirubin in serum. Modified Malloy-Evelyn Diazotization Method. Endpoint Reaction Product measured at 540 nm. Linearity: 20 mg/dl...
... Spectrophotometers are simple, reliable ... use in many types ... clinical, industrial and environmental ... vial holders, Windows based ...
Spectra 5000 is one of the most versatile analytical devices used in conventional laboratories which can work in the ultravoilet and visible range from 200 to 1000 nm for quantitative and qualitative...
... 400 Series Spectrophotometer ... approach to UV-VIS instrumentation. ... are incorporated into a ... in features and performance ...
Medicine Products: